Dr. Alexey V. Danilov
Claim this profileCity of Hope Medical Center
Studies Cancer
Studies Lymphoma
9 reported clinical trials
15 drugs studied
Area of expertise
1Cancer
TP53 positive
CCND1 positive
13q positive
2Lymphoma
13q positive
13q negative
12 positive
Affiliated Hospitals
Clinical Trials Alexey V. Danilov is currently running
Nemtabrutinib + Rituximab
for Mantle Cell Lymphoma
This phase II trial tests how well nemtabrutinib works with rituximab for the treatment of patients with mantle cell lymphoma. Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantel cell lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nemtabrutinib with rituximab may kill more cancer cells in patients with mantle cell lymphoma.
Recruiting1 award Phase 210 criteria
Venetoclax + Obinutuzumab
for Leukemia
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with the venetoclax and obinutuzumab early (before patients have symptoms) may have better outcomes for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared to starting treatment with the venetoclax and obinutuzumab after patients show symptoms.
Recruiting2 awards Phase 31 criteria
More about Alexey V. Danilov
Clinical Trial Related2 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Alexey V. Danilov has experience with
- Rituximab
- Venetoclax
- Acalabrutinib
- Ublituximab
- Umbralisib
- Nemtabrutinib
Breakdown of trials Alexey V. Danilov has run
Cancer
Lymphoma
Lymphoid Leukemia
T-Lymphoblastic Leukemia/Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alexey V. Danilov specialize in?
Alexey V. Danilov focuses on Cancer and Lymphoma. In particular, much of their work with Cancer has involved TP53 positive patients, or patients who are CCND1 positive.
Is Alexey V. Danilov currently recruiting for clinical trials?
Yes, Alexey V. Danilov is currently recruiting for 3 clinical trials in Duarte California. If you're interested in participating, you should apply.
Are there any treatments that Alexey V. Danilov has studied deeply?
Yes, Alexey V. Danilov has studied treatments such as Rituximab, Venetoclax, Acalabrutinib.
What is the best way to schedule an appointment with Alexey V. Danilov?
Apply for one of the trials that Alexey V. Danilov is conducting.
What is the office address of Alexey V. Danilov?
The office of Alexey V. Danilov is located at: City of Hope Medical Center, Duarte, California 91010 United States. This is the address for their practice at the City of Hope Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.